SIH Partners’s Intellia Therapeutics NTLA Stock Holding History

SIH Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,406	Closed	-$95.3K	–	266
2025 Q1	$95.3K	Buy	+13,406	New	+$135K	﹤0.01%	242

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIH Partners's NTLA Position: Q2 2025 in Review

SIH Partners sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 13,406 shares — an estimated $95.3K sold.

SIH Partners first reported a position in NTLA in Q1 2025 and held it in 1 quarter. The position peaked at $95.3K in Q1 2025. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

SIH Partners reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 13,406 Intellia Therapeutics shares in Q2 2025, an estimated $95.3K.
SIH Partners first reported a position in Intellia Therapeutics in Q1 2025 and held it in 1 quarter.
SIH Partners's Intellia Therapeutics position peaked at $95.3K in Q1 2025.
280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.